Hepatocellular carcinoma after prior sorafenib treatment: incidence, healthcare utilisation and costs from German statutory health insurance claims data
Abstract Objective To estimate both the number of patients with hepatocellular carcinoma (HCC) eligible annually for second-line therapy following sorafenib in Germany and the healthcare costs accrued by patients meeting eligibility criteria. Methods Patients with an HCC diagnosis and one or more so...
Main Authors: | Johannes Clouth, Astra M. Liepa, Guido Moeser, Heiko Friedel, Magdalena Bernzen, Jörg Trojan, Elena Garal-Pantaler |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2018-08-01
|
Series: | Health Economics Review |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s13561-018-0199-1 |
Similar Items
-
Burden of HPV related anogenital diseases in young women in Germany – an analysis of German statutory health insurance claims data from 2012 to 2017
by: Miriam Reuschenbach, et al.
Published: (2020-04-01) -
Clinical burden of illness in patients with phenylketonuria (PKU) and associated comorbidities - a retrospective study of German health insurance claims data
by: K. F. Trefz, et al.
Published: (2019-07-01) -
Health economic burden of patients with phenylketonuria (PKU) – A retrospective study of German health insurance claims data
by: Friedrich Trefz, et al.
Published: (2021-06-01) -
Effectiveness of Global Treatment Budgets for Patients With Mental Disorders—Claims Data Based Meta-Analysis of 13 Controlled Studies From Germany
by: Fabian Baum, et al.
Published: (2020-03-01) -
STAKEHOLDERS’ PERCEPTION OF THE INDEPENDENCE OF STATUTORY AUDITORS IN NIGERIA
by: Semiu Babatunde Adeyemi, et al.
Published: (2011-11-01)